A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
PETACH TIKVA, Israel, Jan. 31, 2024 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and...
Financing Led by Leading U.S. Life Sciences-focused InvestorsPETACH TIKVA, Israel, Jan. 04, 2024 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a...
Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of...
Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour SegalPETACH TIKVA, Israel, Nov. 07, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to...
PETACH TIKVA, Israel, Nov. 01, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights...
PETACH TIKVA, Israel, Oct. 11, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that...
PETACH TIKVA, Israel, Oct. 09, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation...
Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. 04, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...
PETACH TIKVA, Israel, Sept. 22, 2023 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company's management will present at the Cantor Global Healthcare Conference...
Successful Audit of the Company's State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX GloballyPETACH TIKVA, Israel, Sept. 21, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...